This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Hidden spread of sebaceous cell carcinoma

Hidden spread of sebaceous cell carcinoma
Reviewed by James Hsuan

5 April 2022 | James Hsuan | EYE - Oculoplastic, EYE - Orbit
Share This

This was a review of 29 patients who had undergone orbital exenteration for sebaceous cell carcinoma. Prompted by the increasing use of topical treatments for intraepithelial disease, the authors were keen to discover the frequency of spread of tumour cells beyond the ocular surface, that might be inadequately treated by drops alone. Of the 29 exenterations, 17 had no tumour nodule or mass, only intraepithelial disease with or without microinvasion. Five of these 17 had evidence of spread beyond the conjunctiva and cornea. One patient had lacrimal gland invasion, two had sac disease and two others had both sac and gland involvement. Of the 12 patients who had a discernible nodule accompanied by intraepithelial Pagetoid spread, three had lacrimal gland disease. The mean survival to tumour-related death was significantly shorter in those who had sac or gland involvement. Overall, 28% of patients had disease involving the lacrimal gland and / or sac. The authors admit that as their cohort dates back to 1997, prior to topical therapies becoming accepted treatment, there may be some bias towards a subgroup of patients with more advanced in-situ disease. However, the high rate of spread beyond the ocular surface does suggest that topical therapy may have significant limitations especially for hidden lacrimal gland disease.

Could extension into the lacrimal gland and sac thwart topical chemotherapy for intraepithelial sebaceous carcinoma?
Gupta T, Vahdani K, Rose GE, et al.
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
2022;38(1):17-21.
Share This
James Hsuan
CONTRIBUTOR
James Hsuan

Aintree University Hospital, Liverpool, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency